Posts by: Charles Moore

Charles Moore

Charles Moore has a long-proven track record in both print and digital journalism, touching on a wide range of subjects, from biotech and healthcare to politics and technology. He contributes substantial feature articles about PH research and development for the news site.

April 6, 2017April 6, 2017

US Patent Dispute Simmers Over Treprostinil-based Therapies for PAH

News, PAH News

U.S. specialty biopharmas SteadyMed and United Therapeutics both issued media releases recently commenting on a ruling by the U.S. Patent and Trademark Office (USPTO) that declared invalid a United Therapeutics patent related to ... Read more

March 17, 2017March 17, 2017

Mifcare Receives Support from HTaPFrance, Inserm to Develop New PAH Therapies

News, PAH News, PH News

Paris-based biotechnology company Mifcare is getting support from the French pulmonary hypertension patients’ association HTaPFrance for the development of new anti-inflammatory therapies for pulmonary arterial hypertension (PAH). Melanie Gallant-Dewavrin, director of HTaPFrance, said ... Read more

December 19, 2016December 19, 2016

SteadyMed Hires Pulmonary Hypertension Advocacy Veteran

News

SteadyMed Therapeutics, a California-based specialty pharmaceutical company that develops drug products for treating orphan and high-value diseases with unmet non-oral delivery needs, has hired Carl Hicks, Jr. to take on ... Read more

November 23, 2016November 23, 2016

BePHenomenal.com Aims to Educate and Engage People with PH

News

November is Pulmonary Hypertension Awareness Month and, in recognition, SteadyMed has announced the launch of its new website, BePHenomenal.com, dedicated to educating people with pulmonary hypertension (PH) so as to empower ... Read more

September 13, 2016September 13, 2016

PH Patients in Canada Urged to Sign Petition for Public Funding of Newer Treatments

News

Serena Lawrence, a young Canadian living with pulmonary hypertension (PH), has launched an online petition to raise public consciousness of, and draw government attention to, PH in Canada. Upon receiving ... Read more

July 13, 2016December 19, 2018

Pulmonary Hypertension: One Family’s Long, Hard Journey

News, PAH News, PH News

Erica Huntzinger, today a pulmonary hypertension (PH) activist and advocate, remembers her mother, Susan, beginning to experience PH symptoms in her mid-30s, but going improperly undiagnosed for more than a quarter century. ... Read more

June 1, 2016June 1, 2016

Reata to Use IPO to Further Develop Bardoxolone Methyl as a Pulmonary Hypertension Therapy

News

Reata Pharmaceuticals, Inc., recently announced in a press release the pricing of its initial public offering of 5,500,000 shares of its Class A common stock at $11.00 per share, before underwriting discounts ... Read more

May 5, 2016May 5, 2016

PHA Canada Marks World PH Day with Release of a Personal, and Informational, Video

News

The Pulmonary Hypertension Association of Canada will join more than 80 other organizations worldwide to mark World Pulmonary Hypertension Day, an international event that raising awareness of pulmonary hypertension (PH). Celebrated on May ... Read more

April 25, 2016April 25, 2016

Step Up for PHAwareness on World Pulmonary Hypertension Day May 5

News

On May 5, more than 80 organizations around the world will participate in activities designed to raise awareness of this often-misdiagnosed disease and to celebrate the lives of people living ... Read more

December 9, 2015December 9, 2015

Novel PAH Cell Therapy Shows Safety in Early Phase 1 Results

News, PAH News

Haifa, Israel-based Pluristem Therapeutics Inc. announced that it has received a notice from United Therapeutics Corporation ending its licensing agreement for development of the cell-based candidate PLX-PAD for the treatment of ... Read more